My ePortfolio Register   

New insights in Merkel cell biology and treatment

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.05.17
Views: 1596

Dr Paul Nghiem - University of Washington, Seattle, USA

Dr Nghiem speaks with ecancer at EADO 2017 about recent updates in treatment options for Merkel cell carcinoma.

He considers response rates to immunotherapy and ongoing biomarker surveillance as guidance for combination therapy.

Dr Nghiem spoke with ecancer at AACR 2016 about using pembrolizumab as treatment, and data on avelumab for metastatic MCC was presented at AACR 2017 by Dr Howard Kaufman.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence